Irene C Waizenegger

2PUBLICATIONS
25CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (2)

|Sep 09, 2024
Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers.

Birgit Wilding, Lydia Woelflingseder, Anke Baum

|Jun 27, 2022
Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses.

Markus Zettl, Melanie Wurm, Otmar Schaaf

Pageof 1

Frequent Collaborators

1 joint publications

Birgit Wilding

1 joint publications

Lydia Woelflingseder

1 joint publications

Anke Baum

1 joint publications

Krzysztof Chylinski